{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:28Z","timestamp":1787614828668,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jad.2024.07.030","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:04:47Z","timestamp":1721088287000},"page":"816-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review"],"prefix":"10.1016","volume":"362","author":[{"given":"Sabrina","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Vasudeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakila","family":"Meshkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jad.2024.07.030_bb0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jnc.14612","article-title":"The blocking of kappa-opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization","volume":"148","author":"Azocar","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jad.2024.07.030_bb5000","series-title":"Veritas Health Innovation, Melbourne, Australia","author":"Covidence systematic review software","year":"2024"},{"key":"10.1016\/j.jad.2024.07.030_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.837671","article-title":"The kappa opioid receptor: a promising therapeutic target for multiple pathologies","volume":"13","author":"Dalefield","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2024.07.030_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jpsychires.2022.12.024","article-title":"Evaluating anhedonia as a risk factor in suicidality: a meta-analysis","volume":"158","author":"Gillissie","year":"2023","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.jad.2024.07.030_bb0020","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.8b01679","article-title":"Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140)","volume":"62","author":"Guerrero","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jad.2024.07.030_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jad.2024.07.030_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.jad.2024.07.030_bb0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2015.05.023","article-title":"Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice","volume":"97","author":"Jackson","year":"2015","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.jad.2024.07.030_bb0040","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1007\/s00213-020-05649-y","article-title":"The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice","volume":"237","author":"Jacobson","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2024.07.030_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108254","article-title":"Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling","volume":"177","author":"Jacobson","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2024.07.030_bb0050","author":"Janssen Research & Development"},{"issue":"4","key":"10.1016\/j.jad.2024.07.030_bb0055","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12799","article-title":"A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior","volume":"25","author":"Jones","year":"2020","journal-title":"Addict. Biol."},{"issue":"5","key":"10.1016\/j.jad.2024.07.030_bb0060","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","article-title":"A randomized proof-of-mechanism trial applying the \u2018fast-fail\u2019 approach to evaluating \u03ba-opioid antagonism as a treatment for anhedonia","volume":"26","author":"Krystal","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jad.2024.07.030_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2014.00170","article-title":"The kappa opioid receptor: from addiction to depression, and back","volume":"5","author":"Lalanne","year":"2014","journal-title":"Front. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2024.07.030_bb0070","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jcph.286","article-title":"Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects","volume":"54","author":"Lowe","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jad.2024.07.030_bb0075","first-page":"7","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"issue":"1","key":"10.1016\/j.jad.2024.07.030_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of \u03ba-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.jad.2024.07.030_bb0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/wps.20771","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatry"},{"issue":"10161","key":"10.1016\/j.jad.2024.07.030_bb0090","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jad.2024.07.030_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232864","article-title":"Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology","volume":"15","author":"Margolis","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.jad.2024.07.030_bb0105","author":"Mathew"},{"issue":"3","key":"10.1016\/j.jad.2024.07.030_bb0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2024.07.030_bb0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1017\/S1092852922000116","article-title":"Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine","volume":"28","author":"McIntyre","year":"2023","journal-title":"CNS Spectr."},{"issue":"2","key":"10.1016\/j.jad.2024.07.030_bb0120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.115.229278","article-title":"Receptor Occupancy of the \u03ba-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050","volume":"356","author":"Naganawa","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.jad.2024.07.030_bb0125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/ALN.0000000000004773","article-title":"Opposing effects on descending control of nociception by \u03bc and \u03ba opioid receptors in the anterior cingulate cortex","volume":"140","author":"Navratilova","year":"2024","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jad.2024.07.030_bb0135","series-title":"[cited 2024 Apr 14]. Neumora therapeutics announces initiation of phase 3 clinical program for navacaprant (NMRA-140) in major depressive disorder","author":"Neumora","year":"2023"},{"key":"10.1016\/j.jad.2024.07.030_bb0140","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jad.2024.07.030_bb0145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/npp.2017.205","article-title":"Repeated administration of Opra Kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence","volume":"43","author":"Reed","year":"2018","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2024.07.030_bb0150","series-title":"The Kappa Opioid Receptor [Internet]","first-page":"473","article-title":"Kappa opioid receptor antagonists as potential therapeutics for mood and substance use disorders","author":"Reed","year":"2022"},{"issue":"10","key":"10.1016\/j.jad.2024.07.030_bb0155","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/gps.5356","article-title":"Major depressive disorder and impaired health-related quality of life among US older adults","volume":"35","author":"Rhee","year":"2020","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2024.07.030_bb0160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000535665","article-title":"Neuropsychological assessments of cognitive impairment in major depressive disorder: a systematic review and Meta-analysis with Meta-regression","volume":"93","author":"Rhee","year":"2024","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2024.07.030_bb0165","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","article-title":"LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","volume":"77","author":"Rorick-Kehn","year":"2014","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.jad.2024.07.030_bb0170","first-page":"627","article-title":"STAR*D","volume":"23","author":"Rush","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2024.07.030_bb0175","first-page":"1","article-title":"Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI\/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study","author":"Schmidt","year":"2024","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2024.07.030_bb0180","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2024.07.030_bb0185","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jad.2024.07.030_bb0190","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00213-013-3195-5","article-title":"Role of kappa-opioid receptors in stress and anxiety-related behavior","volume":"229","author":"Van\u2019t Veer","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.jad.2024.07.030_bb0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1527-3458.2003.tb00248.x","article-title":"A review of the properties of spiradoline: a potent and selective k-opioid receptor agonist","volume":"9","author":"Wadenberg","year":"2003","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.jad.2024.07.030_bb0200","author":"Wallace","year":"2019"},{"issue":"21","key":"10.1016\/j.jad.2024.07.030_bb0205","article-title":"Kappa opioid receptor antagonism protects working memory performance from mild stress exposure in Rhesus macaques","author":"Wallace","year":"2022","journal-title":"Neurobiol. Stress."},{"issue":"9","key":"10.1016\/j.jad.2024.07.030_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107536","article-title":"Kappa opioid receptor in nucleus accumbens regulates depressive-like behaviors following prolonged morphine withdrawal in mice","volume":"26","author":"Zhang","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.jad.2024.07.030_bb0215","article-title":"Aticaprant (clinically developed kappa-opioid receptor antagonist) combined with naltrexone prevents alcohol \u201crelapse\u201d drinking","volume":"9","author":"Zhou","year":"2022","journal-title":"J. Pharm. Pharmacol. (Los Angel)."},{"issue":"14","key":"10.1016\/j.jad.2024.07.030_bb0220","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1017\/S0033291722003385","article-title":"The associations between depressive symptoms, functional impairment, and quality of life, in patients with major depression: undirected and Bayesian network analyses","volume":"53","author":"Zhou","year":"2023","journal-title":"Psychol. Med."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724010863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724010863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:53:17Z","timestamp":1742230397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724010863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":43,"alternative-id":["S0165032724010863"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.030","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}